Similarly, Herceptin (trastuzumab) has dramatically boosted the survival rates of

patients suffering from early and metastatic HER2-positive breast cancer. With

chemotherapy, the survival rate used to be 75.2%, which increased to 84% after

the use of Herceptin (Roy et al. 2006; Kantarjian et al. 2012; Hochhaus et al. 2017;

Medicine 2019). To develop precision medicines, it is imperative to combine the

clinical indices with molecular profiling so that diagnostic, prognostic, and thera-

peutic strategies could be established. Therefore, it is crucial to interpret the data

accurately for best use of PM ecosystem as it integrates “omics” and clinical data to

find the best course of action to be taken for each specific patient group (Seyhan and

Carini 2019) (Fig. 1.3).

1.8

Summary and Conclusion

Presently the multidisciplinary research teams are working on a plethora of many

different new emerging and advanced technologies for the discovery of modern

drugs. It is essential to use advanced technologies such as experimental and compu-

tational approaches in integration with the drug discovery programs as it puts high

synergistic effects on the selection and optimization of bioactive compounds. The

technologies such as VS, HTS, SBDD, LBDD, QSAR, and so on have their mutual

goals and are thus complementary. Therefore, the integration of both empirical and

silico efforts is feasible at many different lead optimization levels and new chemical

entity (NCE) discovery. The biomedical community is now applying artificial

intelligence (AI) and machine learning algorithms to manage and study huge

available data. The development and application of wearable medical devices

(e.g., wearable watches), mobile health applications, and clinical outcome data

contributed to the accumulation of substantial data through various molecular

profiling (genetic, genomic, proteomic, epigenomic, and others) efforts of patient

samples. The technological advancement generates new research opportunities in

predictive diagnostics, virtual diagnosis, precision medicine, patient monitoring, and

drug discovery and delivery for targeted therapies. Along with the scientific

communities, the academics, industry researchers, and regulatory agencies are filled

with enthusiasm with these new advancements, and physicians are being provided

with novel tools. Thus, the application of new medical practices can be enhanced by

the use of these highly advanced new age technologies, such as BMs, omics data,

artificial intelligence, and deep machine learning.

1

Emerging Technologies: Gateway to Understand Molecular Insight of. . .

11